Case review of a 68-year-old male with metastatic right-sided colon adenocarcinoma with KRAS A146V mutation. Frontline biomarker testing with OmniSeq INSIGHT provided initial options for therapy, but when his tumor progressed rapidly, Labcorp Plasma Focus liquid biopsy helped his oncologist determine next line of therapy.

This study investigates associations between markers of genomic instability and genomic defects in genes associated with homologous recombination (HR) in a cohort of 431 prostate cancer specimens.

A significant portion of cancer patients are initially diagnosed with localized disease and are eligible for curative interventions. However, residual tumors cells, representing molecular residual disease (MRD), remaining after these interventions might result in disease recurrence.

In solid tumors without routine HER2 expression assessment and no approved anti-HER2 treatments, comprehensive genomic profiling (CGP) is crucial, as it not only helps determine eligibility for existing targeted therapies but also identifies genomic ERBB2 alterations that could respond to emerging anti-HER2 antibody-drug conjugates in clinical dev

Labcorp® Plasma Complete™ is a comprehensive next generation sequencing (NGS), cell free DNA profiling test that identifies clinically relevant variants in advanced and metastatic solid tumors across 521 genes as well as microsatellite instability (MSI).